• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by BillionToOne Inc.

    2/13/26 2:45:31 PM ET
    $BLLN
    Medical Specialities
    Health Care
    Get the next $BLLN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    BillionToOne, Inc.

    (Name of Issuer)


    Class A Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    090168105

    (CUSIP Number)


    11/07/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    090168105


    1Names of Reporting Persons

    NeoTribe Ventures I, L.P. ("NTV I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,710,286.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,710,286.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,710,286.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Note to Rows 5 and 7: NeoTribe Partners I, LLC ("NTP I"), the general partner of NTV I, may be deemed to have sole voting and dispositive power over these shares, and Kolluri, the managing member of NTP I, may be deemed to have sole voting and dispositive power over these shares. Note to Row 6: See response to Row 5. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 41,216,110 shares of Class A Common Stock, par value $0.00001 per share ("Common Stock") outstanding as of December 5, 2025, as set forth in the quarterly report on Form 10-Q of BillionToOne, Inc. (the "Issuer") for the quarter ended September 30, 2025, filed with the United States Securities and Exchange Commission (the "Commission") on December 10, 2025 (the "Form 10-Q").


    SCHEDULE 13G

    CUSIP No.
    090168105


    1Names of Reporting Persons

    NeoTribe Associates I, L.P. ("NTA I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    109,204.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    109,204.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    109,204.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Note to Rows 5 and 7: All shares are held of record by NTV I as nominee for NTA I. NTP I, the general partner of NTA I, may be deemed to have sole voting and dispositive power over these shares, and Kolluri, the managing member of NTP I, may be deemed to have sole voting and dispositive power over these shares. Note to Row 6: See response to Row 5. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 41,216,110 shares of Common Stock outstanding as of December 5, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    090168105


    1Names of Reporting Persons

    NeoTribe Partners I, LLC ("NTP I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,819,490.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,819,490.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,819,490.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Note to Rows 5 and 7: Consists of 2,710,286 shares held of record by NTV I for itself and 109,204 shares held of record by NTV I as nominee for NTA I. NTP I, the general partner of NTV I and NTA I, may be deemed to have sole voting and dispositive power over these shares, and Kolluri, the managing member of NTP I, may be deemed to have sole voting and dispositive power over these shares. Note to Row 6: See response to Row 5. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 41,216,110 shares of Common Stock outstanding as of December 5, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    090168105


    1Names of Reporting Persons

    Neotribe Ignite Fund I, L.P. ("NTIF I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,297,799.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,297,799.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,297,799.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Note to Rows 5 and 7: Neotribe Ignite Partners I, LLC ("NTIP I"), the general partner of NTIF I, may be deemed to have sole voting and dispositive power over these shares, and Kolluri, the managing member of NTIP I, may be deemed to have sole voting and dispositive power over these shares. Note to Row 6: See response to Row 5. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 41,216,110 shares of Common Stock outstanding as of December 5, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    090168105


    1Names of Reporting Persons

    Neotribe Ignite Partners I, LLC ("NTIP I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,297,799.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,297,799.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,297,799.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Note to Rows 5 and 7: Shares held of record by NTIF I. NTIP I, the general partner of NTIF I, may be deemed to have sole voting and dispositive power over these shares, and Kolluri, the managing member of NTIF I, may be deemed to have sole voting and dispositive power over these shares. Note to Row 6: See response to Row 5. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 41,216,110 shares of Common Stock outstanding as of December 5, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    090168105


    1Names of Reporting Persons

    Neotribe SPV I BTO, LLC ("NT SPV I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    242,216.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    242,216.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    242,216.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.6 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Note to Rows 5 and 7: Neotribe Partners SPV I BTO, LLC ("NTP SPV I"), the managing member of NT SPV I, may be deemed to have sole voting and dispositive power over these shares, and Kolluri, the managing member of NTP SPV I, may be deemed to have sole voting and dispositive power over these shares. Note to Row 6: See response to Row 5. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 41,216,110 shares of Common Stock outstanding as of December 5, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    090168105


    1Names of Reporting Persons

    Neotribe Partners SPV I BTO, LLC ("NTP SPV I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    242,216.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    242,216.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    242,216.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.6 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Note to Row 5: Shares held of record by NT SPV I. NTP SPV I, the managing member of NT SPV I, may be deemed to have sole voting and dispositive power over these shares, and Kolluri, the managing member of NT SPV I, may be deemed to have sole voting and dispositive power over these shares. Note to Row 6: See response to Row 5. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 41,216,110 shares of Common Stock outstanding as of December 5, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    090168105


    1Names of Reporting Persons

    Krishna Kittu Kolluri ("Kolluri")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,359,505.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,359,505.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,359,505.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.6 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Note to Rows 5 and 7: Consists of 2,710,286 shares held of record by NTV I for itself, 109,204 shares held of record by NTV I as nominee for NTA I, 1,297,799 shares held of record by NTIF I and 242,216 shares held of record by NT SPV I. NTP I, the general partner of NTV I and NTA I, may be deemed to have sole voting and dispositive power over the shares held of record by NTV I for itself and as nominee for NTA I. NTIP I, the general partner of NTIF I, may be deemed to have sole voting and dispositive power over the shares held of record by NTIF I. NTP SPV I, the managing member of NT SPV I, may be deemed to have sole voting and dispositive power over the shares held of record by NT SPV I. Kolluri, a director of the Issuer and the managing member of NTP I, NTIP I and NTP SPV I may be deemed to have sole voting and dispositive power over the shares held of record by NTV I for itself and as nominee for NTA I, NTIF I and NT SPV I, respectively. Note to Row 6: See response to Row 5. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 41,216,110 shares of Common Stock outstanding as of December 5, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BillionToOne, Inc.
    (b)Address of issuer's principal executive offices:

    1035 O'Brien Drive, Menlo Park, CA 94025
    Item 2. 
    (a)Name of person filing:

    This joint statement on Schedule 13G is being filed by NeoTribe Ventures I, L.P. ("NTV I"), NeoTribe Associates I, L.P. ("NTA I"), NeoTribe Partners I, LLC ("NTP I"), Neotribe Ignite Fund I, L.P. ("NTIF I"), Neotribe Ignite Partners I, LLC ("NTIP I"), Neotribe SPV I BTO, LLC ("NT SPV I"), Neotribe Partners SPV I BTO, LLC ("NTP SPV I") and Krishna Kolluri ("Kolluri"). The foregoing entities and individuals are collectively referred to as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    c/o NeoTribe Management Company, LLC 1300 El Camino Real, Suite 100 Menlo Park, CA 94025
    (c)Citizenship:

    See Row 4 of cover page for each Reporting Person.
    (d)Title of class of securities:

    Class A Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    090168105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.
    (b)Percent of class:

    See Row 11 of cover page for each Reporting Person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Under certain circumstances set forth in the limited partnership agreements of NTV I, NTA I and NTIF I, and the limited liability company agreement of NTP I, NTIP I, NT SPV I and NTP SPV I, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    NeoTribe Ventures I, L.P. ("NTV I")
     
    Signature:/s/ Krishna Kolluri
    Name/Title:Managing Member of NeoTribe Partners I, LLC, the General Partner of NeoTribe Ventures I, L.P.
    Date:02/13/2026
     
    NeoTribe Associates I, L.P. ("NTA I")
     
    Signature:/s/ Krishna Kolluri
    Name/Title:Managing Member of NeoTribe Partners I, LLC, the General Partner of NeoTribe Associates I, L.P.
    Date:02/13/2026
     
    NeoTribe Partners I, LLC ("NTP I")
     
    Signature:/s/ Krishna Kolluri
    Name/Title:Managing Member
    Date:02/13/2026
     
    Neotribe Ignite Fund I, L.P. ("NTIF I")
     
    Signature:/s/ Krishna Kolluri
    Name/Title:Managing Member of Neotribe Ignite Partners I, LLC, the General Partner of Neotribe Ignite Fund I, L.P.
    Date:02/13/2026
     
    Neotribe Ignite Partners I, LLC ("NTIP I")
     
    Signature:/s/ Krishna Kolluri
    Name/Title:Managing Member
    Date:02/13/2026
     
    Neotribe SPV I BTO, LLC ("NT SPV I")
     
    Signature:/s/ Krishna Kolluri
    Name/Title:Managing Member of Neotribe Partners SPV I BTO, LLC, the Managing Member of Neotribe SPV I BTO, LLC
    Date:02/13/2026
     
    Neotribe Partners SPV I BTO, LLC ("NTP SPV I")
     
    Signature:/s/ Krishna Kolluri
    Name/Title:Managing Member
    Date:02/13/2026
     
    Krishna Kittu Kolluri ("Kolluri")
     
    Signature:/s/ Krishna Kolluri
    Name/Title:Krishna Kolluri
    Date:02/13/2026
    Exhibit Information

    Exhibit A: Joint Filing Agreement

    Get the next $BLLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLLN

    DatePrice TargetRatingAnalyst
    1/6/2026$120.00Buy
    Guggenheim
    12/1/2025Outperform
    William Blair
    12/1/2025$117.00Hold
    Jefferies
    12/1/2025$150.00Overweight
    Analyst
    12/1/2025$150.00Overweight
    Piper Sandler
    12/1/2025$145.00Buy
    Stifel
    12/1/2025$110.00Equal Weight
    Wells Fargo
    12/1/2025$160.00Buy
    BTIG Research
    More analyst ratings

    $BLLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested l

    4/15/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

    Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategyMENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology. This new appointment reflects BillionToOne's continued commitment to building world-class oncology medical leadership as the company grows its Northstar liquid biopsy portfolio.

    4/2/26 9:00:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights: Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%.Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024.Oncology clinical testing revenue was $9.1 milli

    3/4/26 4:05:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    SEC Filings

    View All

    SEC Form DEFA14A filed by BillionToOne Inc.

    DEFA14A - BillionToOne, Inc. (0002070849) (Filer)

    4/21/26 4:26:02 PM ET
    $BLLN
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by BillionToOne Inc.

    DEF 14A - BillionToOne, Inc. (0002070849) (Filer)

    4/21/26 4:25:37 PM ET
    $BLLN
    Medical Specialities
    Health Care

    SEC Form 10-K filed by BillionToOne Inc.

    10-K - BillionToOne, Inc. (0002070849) (Filer)

    3/11/26 4:55:45 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Humming Bird Ventures Management Nv disposed of 7,887,187 shares, acquired 7,887,187 shares and converted options into 7,707,188 shares (SEC Form 4)

    4 - BillionToOne, Inc. (0002070849) (Issuer)

    1/20/26 7:27:56 PM ET
    $BLLN
    Medical Specialities
    Health Care

    New insider Humming Bird Ventures Management Nv claimed ownership of 179,999 shares (SEC Form 3)

    3 - BillionToOne, Inc. (0002070849) (Issuer)

    1/20/26 7:25:53 PM ET
    $BLLN
    Medical Specialities
    Health Care

    Director Pagano Anthony was granted 4,896 shares (SEC Form 4)

    4 - BillionToOne, Inc. (0002070849) (Issuer)

    1/5/26 8:52:49 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Leadership Updates

    Live Leadership Updates

    View All

    BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

    Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategyMENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology. This new appointment reflects BillionToOne's continued commitment to building world-class oncology medical leadership as the company grows its Northstar liquid biopsy portfolio.

    4/2/26 9:00:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair

    MENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026. Mr. Pagano will also serve as Chair of the Audit Committee. Mr. Pagano is currently Chief Financial Officer and Executive Vice President of Genmab, a leading international biotechnology company, a position he has held since March 2020. He joined Genmab in December 200

    12/9/25 4:07:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Financials

    Live finance-specific insights

    View All

    BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested l

    4/15/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights: Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%.Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024.Oncology clinical testing revenue was $9.1 milli

    3/4/26 4:05:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. To participate in the conference call, please register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast will be available

    2/17/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on BillionToOne with a new price target

    Guggenheim initiated coverage of BillionToOne with a rating of Buy and set a new price target of $120.00

    1/6/26 8:54:21 AM ET
    $BLLN
    Medical Specialities
    Health Care

    William Blair initiated coverage on BillionToOne

    William Blair initiated coverage of BillionToOne with a rating of Outperform

    12/1/25 8:36:56 AM ET
    $BLLN
    Medical Specialities
    Health Care

    Jefferies initiated coverage on BillionToOne with a new price target

    Jefferies initiated coverage of BillionToOne with a rating of Hold and set a new price target of $117.00

    12/1/25 8:27:06 AM ET
    $BLLN
    Medical Specialities
    Health Care